Physician profile
Wafa Abbud
NPI 1871581322
$1,805.08
in general payments reported to CMS, 2019-2025
18 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $37.07 · 2021: $46.16 · 2022: $182 · 2023: $388 · 2024: $664 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $306.66 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $287.04 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $277.85 | 2023-2025 | |
| Glaxosmithkline, LLC. | $192.81 | 2019-2024 | Arexvy |
| Novartis Pharmaceuticals Corporation | $112.78 | 2019-2023 | |
| Exact Sciences Corporation | $94.76 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $82.45 | 2021-2024 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $78.36 | 2023-2024 | Veozah |
| Amgen INC. | $76.21 | 2019-2022 | |
| Pfizer INC. | $46.20 | 2024-2025 | |
| Abbvie INC. | $45.69 | 2021-2024 | Vraylar |
| Sumitomo Pharma America, INC. | $45.25 | 2023-2024 | Gemtesa |
| Bioventus LLC | $44.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $40.81 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $22.74 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.45 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $17.78 | 2025 | Rexulti |
| Myovant Sciences INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wafa Abbud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.